Alveo Announces Appointments of CTO and Director of Assay Development
Published: Jul 12, 2018
SAN FRANCISCO, July 12, 2018 /PRNewswire/ -- Alveo Technologies, Inc., ("Alveo" or "the Company") a medical diagnostics firm whose mission is to create affordable and accessible infectious disease diagnostics, announced today the appointments of two leadership roles. Johnson Chiang, Ph.D., has been named Chief Technology Officer and Rixun Fang, Ph.D., has been appointed Director of Assay Development.
"We are beyond pleased to welcome Johnson and Rixun to the team," shared Ron Chiarello, Ph.D, Founder and CEO. "Not only are they brilliant leaders in their fields, but they share the Alveo passion for creating better, more accessible ways to protect the health of humankind."
In his role as Chief Technology Officer, Dr. Chiang has a clear mission to ensure the success of Alveo's high-performance product development and commercialization. He and his team are focused on ensuring the technology reaches its full potential, through FDA approval and into the market: "We know the technology works well. It is now in our hands to realize it, and to get the lowest cost, easy to use, most effective form of the product to as many people as possible - making early detection a reality."
Previously, Dr. Chiang was Head of Systems Integration and Molecular Biology at Foundation Medicine, Inc. and held senior management positions at Life Technologies and Thermo Fisher Scientific; leading systems design, integration, verification and validation for qPCR and Next-Gen Sequencing platforms. Dr. Chiang has led a number of molecular diagnostic product development projects from concept to commercialization at Applied MEMS, Applied Biosystems Inc., and Cepheid; designed and developed several successful microfluidics products; filed several patents; and published numerous biotechnology papers. He also has extensive experience in instrument development as well as design control for 510k and PMA applications.
As Director of Assay Development, Dr. Fang brings over 20 years of experience in molecular biology research and IVD product development to Alveo. He has successfully led many projects from inception through development and implementation at Applied Biosystems, Life Technologies, and Thermo Fisher Scientific, following GMP/QSR/ISO compliances and the PCP process.
"I was really impressed, first and foremost, with the technology, which will revolutionize the practice of molecular diagnostics. The speed, low energy requirements, and ease of use make it accessible to a much greater population, even to families in remote areas with minimal resources. We have the ability to really help people, to save lives." Dr. Fang has worked through IVD product 510k and PMA submissions with FDA, initiated and led collaborative projects with many internationally well-known institutions, holds 6 patents, and has authored dozens of publications.
ABOUT ALVEO TECHNOLOGIES
Alveo is a pre-clinical stage medical diagnostics company that is creating a new ecosystem for the detection of diseases by breaking down the barriers between consumers, patients, donors, and conventional healthcare systems. To learn more about the award-winning team and the science behind the technology visit www.alveotechnologies.com.
1000 Atlantic Avenue
Alameda, California 94501
View original content with multimedia:http://www.prnewswire.com/news-releases/alveo-announces-appointments-of-cto-and-director-of-assay-development-300680254.html
SOURCE Alveo Technologies